{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T23:01:39Z","timestamp":1770332499345,"version":"3.49.0"},"reference-count":80,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ethypharm GmbH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Opioid use disorder (OUD) is a chronic relapsing condition associated with elevated mortality and substantial psychiatric and somatic comorbidity. Oral methadone and sublingual and depot buprenorphine are the undisputed gold standard in opioid agonist treatment (OAT). More recently, another oral buprenorphine formulation, buprenorphine lyophilisate (BUP-Lyo), has been introduced into clinical practice, offering potentially faster bioavailability and simplified administration. This review aims to summarize the available clinical and pharmacological data on BUP-Lyo and assess its potential role within current OAT strategies. Methods: A targeted Medline search was performed to identify publications reporting pharmacological characteristics, safety, efficacy, and clinical use of BUP-Lyo. Additional information was requested from the manufacturer. Relevant sources were reviewed narratively with a focus on OUD treatment, with particular attention to the pharmacological and clinical profile of the compound. Results: Few studies on BUP-Lyo have been published to date. As a rapid-dispersion formulation placed on the tongue, BUP-Lyo provides faster bioavailability and a quicker route of administration compared with conventional sublingual buprenorphine. These properties may reduce the need for post-administration supervision and could lessen risks of misuse or diversion. Available evidence supports its safety, efficacy, and feasibility within routine OAT, and the clinical implications of these characteristics are discussed. Conclusions: BUP-Lyo expands the range of available buprenorphine formulations and offers practical advantages through accelerated absorption and simplified administration. While initial data are encouraging, the limited evidence base underscores the need for further longitudinal and post-marketing studies to define its clinical position in the management of OUD.<\/jats:p>","DOI":"10.3390\/ph19020270","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:35:37Z","timestamp":1770287737000},"page":"270","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Buprenorphine Oral Lyophilisate for Treatment of Opioid Use Disorder: Pharmacology and Clinical Efficacy"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8771-9151","authenticated-orcid":false,"given":"Michael","family":"Soyka","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Nussbaumstra\u00dfe 7, 80336 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svenja","family":"Bolz","sequence":"additional","affiliation":[{"name":"Ethypharm GmbH, 12529 Sch\u00f6nefeld, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2010). International Classification of Diseases, 10th Revision (ICD-10), World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/14656566.2025.2507124","article-title":"Approved medications for opioid use disorder: Current update","volume":"26","author":"Soyka","year":"2025","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Publishing. [5th ed.].","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref_4","unstructured":"(2018). GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392, 1789\u20131858."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zhang, J., Liu, R., Wang, X., Zhang, L., Pei, W., Hou, J., and Li, S. (2025). Global burden, socioeconomic disparities, and spatiotemporal dynamics of opioid use disorder mortality and disability: A comprehensive analysis from the Global Burden of Disease Study 2017\u20132021. BMC Public Health, 25.","DOI":"10.1186\/s12889-025-24541-y"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","article-title":"Global patterns of opioid use and dependence: Harms to populations, interventions, and future action","volume":"394","author":"Degenhardt","year":"2019","journal-title":"Lancet"},{"key":"ref_7","unstructured":"United Nations Office on Drugs and Crime (UNODC) (2024). World Drug Report 2024, United Nations Publication."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1360-0443.2010.03140.x","article-title":"Mortality among regular or dependent users of heroin and other opioids: A systematic review and meta-analysis of cohort studies","volume":"106","author":"Degenhardt","year":"2011","journal-title":"Addiction"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder","volume":"87","author":"Bell","year":"2020","journal-title":"Biol. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/ADM.0000000000000635","article-title":"Executive summary of the focused update of the ASAM National Practice Guideline for the Treatment of Opioid Use Disorder","volume":"14","author":"Crotty","year":"2020","journal-title":"J. Addict. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100341","DOI":"10.1016\/j.lanepe.2022.100341","article-title":"The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990\u20132019: Findings from the Global Burden of Disease Study 2019","volume":"16","author":"Castelpietra","year":"2022","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Giraudon, I., Abel-Ollo, K., Vanaga-Ar\u0101ja, D., Heudtlass, P., and Griffiths, P. (2024). Nitazenes represent a growing threat to public health in Europe. Lancet Public Health, 9.","DOI":"10.1016\/S2468-2667(24)00024-0"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.15585\/mmwr.mm6450a3","article-title":"Increases in drug and opioid overdose deaths\u2014United States, 2000\u20132014","volume":"64","author":"Rudd","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jama.2017.8913","article-title":"New data on opioid use and prescribing in the United States","volume":"318","author":"Schuchat","year":"2017","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Wise, J. (2024). Nitazenes: Toxicologists warn of rise in overdoses linked to class of synthetic opioids. BMJ, 387.","DOI":"10.1136\/bmj.q2465"},{"key":"ref_16","unstructured":"Dhaliwal, A., and Gupta, M. (2023, July 24). Physiology, Opioid Receptor, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538489\/."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","article-title":"Opioid use disorder","volume":"6","author":"Strang","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.copsyc.2018.07.014","article-title":"A review of opioid addiction genetics","volume":"27","author":"Crist","year":"2019","journal-title":"Curr. Opin. Psychol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/psychoactives3010003","article-title":"Neurobiological theories of addiction: A comprehensive review","volume":"3","author":"Romero","year":"2024","journal-title":"Psychoactives"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biopsych.2019.05.023","article-title":"Neurobiology of opioid addiction: Opponent process, hyperkatifeia, and negative reinforcement","volume":"87","author":"Koob","year":"2020","journal-title":"Biol. Psychiatry"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Johnson, E.O., Fisher, H.S., Sullivam, K.A., Corradin, O., Sanchez-Roige, S., Gaddis, N.C., Sami, Y.N., Townsend, A., Teixeira Prates, E., and Pavicic, M. (2024). An emerging multi-omic understanding of the genetics of opioid addiction. J. Clin. Investig., 134.","DOI":"10.1172\/JCI172886"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: Development, challenges and opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJMra1511480","article-title":"Neurobiologic advances from the brain disease model of addiction","volume":"374","author":"Volkow","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1152\/physrev.00014.2018","article-title":"The neuroscience of drug reward and addiction","volume":"99","author":"Volkow","year":"2019","journal-title":"Physiol. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2174\/1871527311312010017","article-title":"Opioid withdrawal syndrome: Emerging concepts and novel therapeutic targets","volume":"12","author":"Rehni","year":"2013","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/pubmed\/fdx063","article-title":"Morbidity and mortality in opioid dependent patients after entering an opioid pharmacotherapy compared with a cohort of non-dependent controls","volume":"40","author":"Kelty","year":"2018","journal-title":"J. Public Health"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1360-0443.2009.02826.x","article-title":"Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review","volume":"105","author":"Larney","year":"2010","journal-title":"Addiction"},{"key":"ref_29","first-page":"136","article-title":"Management for drug use disorders: Meta-analysis and application of Tolin\u2019s criteria","volume":"31","author":"Pfund","year":"2024","journal-title":"Clin. Psychol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/add.13644","article-title":"Psychosocial interventions in opiate substitution treatment services: Does the evidence provide a case for optimism or nihilism?","volume":"112","author":"Day","year":"2017","journal-title":"Addiction"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000193","article-title":"A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction","volume":"10","author":"Dugosh","year":"2016","journal-title":"J. Addict. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"108434","DOI":"10.1016\/j.drugalcdep.2020.108434","article-title":"Forty-eight years of research on psychosocial interventions in the treatment of opioid use disorder: A scoping review","volume":"218","author":"Wild","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Ray, L.A., Meredith, L.R., Kiluk, B.D., Walthers, J., Carroll, K.M., and Magill, M. (2020). Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: A systematic review and meta-analysis. JAMA Netw. Open, 3.","DOI":"10.1001\/jamanetworkopen.2020.8279"},{"key":"ref_34","unstructured":"Simpson, D.D., and Sells, S.B. (1990). Opioid Addiction and Treatment: A 12-Year Follow-Up, Robert E. Krieger Publishing."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"115318","DOI":"10.1016\/j.psychres.2023.115318","article-title":"Meta-review on the efficacy of psychological therapies for the treatment of substance use disorders","volume":"326","author":"Dellazizzo","year":"2024","journal-title":"Psychiatry Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Berglund, M., Thelander, S., and Jonsson, E. (2003). Treating Alcohol and Drug Abuse: An Evidence-Based Review, Wiley-VCH.","DOI":"10.1002\/3527601465"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1176\/appi.ajp.2007.06111851","article-title":"A meta-analytic review of psychosocial interventions for substance use disorders","volume":"165","author":"Dutra","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Amato, L., Minozzi, S., Davoli, M., and Vecchi, S. (2011). Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst. Rev., 10.","DOI":"10.1002\/14651858.CD004147.pub4"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Amato, L., Minozzi, S., Davoli, M., and Vecchi, S. (2011). Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst. Rev., 9.","DOI":"10.1002\/14651858.CD005031.pub4"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamapsychiatry.2021.0247","article-title":"Cost-effectiveness of treatments for opioid use disorder","volume":"78","author":"Fairley","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Mattick, R.P., Breen, C., Kimber, J., and Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev., 2003.","DOI":"10.1002\/14651858.CD002209"},{"key":"ref_42","unstructured":"World Health Organization (2025). Opiod agonist maintenance treatment as an essential service. Guidance on Mitigating Disruption of Services for Treatment of Opioid Dependence and Community Management of Opioid Overdose, WHO."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"ASAM (2020). The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J. Addict. Med., 14, 1\u201391.","DOI":"10.1097\/ADM.0000000000000633"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/add.12440","article-title":"Maintenance treatment for opioid dependence with slow-release oral morphine: A randomized cross-over, non-inferiority study versus methadone","volume":"109","author":"Beck","year":"2014","journal-title":"Addiction"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s40265-018-0962-y","article-title":"Supervised injectable opioid treatment for the management of opioid dependence","volume":"78","author":"Bell","year":"2018","journal-title":"Drugs"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Ferri, M., Minozzi, S., Bo, A., and Amato, L. (2013). Slow-release oral morphine as maintenance therapy for opioid dependence (Review). Cochrane Database Syst. Rev., 6.","DOI":"10.1002\/14651858.CD009879.pub2"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa0810635","article-title":"Diacetylmorphine versus methadone for the treatment of opioid addiction","volume":"361","author":"Brissette","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1001\/jamapsychiatry.2016.0109","article-title":"Hydromorphone compared with diacetylmorphine for long-term opioid dependence: A randomized clinical trial","volume":"73","author":"Guh","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.drugalcdep.2017.02.021","article-title":"Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder","volume":"176","author":"Brissette","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874473711104010028","article-title":"Buprenorphine and buprenorphine\/naloxone diversion, misuse, and illicit use: An international review","volume":"4","author":"Yokell","year":"2011","journal-title":"Curr. Drug Abus. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Gowing, L., Ali, R., White, J.M., and Mbewe, D. (2017). Buprenorphine for managing opioid withdrawal. Cochrane Database Syst. Rev., 2.","DOI":"10.1002\/14651858.CD002025.pub5"},{"key":"ref_52","first-page":"1","article-title":"Optimal dose of buprenorphine in opioid use disorder treatment: A review of pharmacodynamic and efficacy data","volume":"46","author":"Nordbeck","year":"2020","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"104748","DOI":"10.1016\/j.drugpo.2025.104748","article-title":"Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of commercially insured individuals with opioid use disorder in the United States","volume":"138","author":"Ivasiy","year":"2025","journal-title":"Int. J. Drug Policy"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2215-0366(15)00366-1","article-title":"Mortality risk of opioid substitution therapy with methadone versus buprenorphine: A retrospective cohort study","volume":"2","author":"Kimber","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"O\u2019Connor, A.M., Cousins, G., Durand, L., Barry, J., and Roland, F. (2020). Retention of patients in opioid substitution treatment: A systematic review. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0232086"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/SAR.S155843","article-title":"Depot buprenorphine injection in the management of opioid use disorder: From development to implementation","volume":"10","author":"Ling","year":"2019","journal-title":"Subst. Abus. Rehabil."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/10550887.2011.642758","article-title":"Effect of buprenorphine dose on treatment outcome","volume":"31","author":"Fareed","year":"2012","journal-title":"J. Addict. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1080\/00952990.2023.2251653","article-title":"Meta-analysis of primary care\u2013delivered buprenorphine treatment retention outcomes","volume":"49","author":"Cooper","year":"2023","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11090","article-title":"Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation","volume":"11","author":"Connock","year":"2007","journal-title":"Health Technol. Assess."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Mattick, R.P., Breen, C., Kimber, J., and Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev., 2014.","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: A systematic review and meta-analysis","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/acps.13477","article-title":"A comparison of mortality rates for buprenorphine versus methadone treatments for opioid use disorder","volume":"147","author":"Gottlieb","year":"2023","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Sordo, L., Barrio, G., Bravo, M.J., Indave, B.I., Degenhardt, L., Wiessing, L., Ferri, M., and Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ, 357.","DOI":"10.1136\/bmj.j1550"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000457","article-title":"Buprenorphine pharmacology review: Update on transmucosal and long-acting formulations","volume":"13","author":"Coe","year":"2019","journal-title":"J. Addict. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1055\/a-1298-4508","article-title":"Novel long-acting buprenorphine medications for opioid dependence: Current update","volume":"54","author":"Soyka","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/ajad.12288","article-title":"Treatment outcomes in opioid-dependent patients with different buprenorphine\/naloxone induction dosing patterns and trajectories","volume":"24","author":"Jacobs","year":"2015","journal-title":"Am. J. Addict."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: A systematic review and meta-analysis of randomized and observational studies","volume":"10","author":"Degenhardt","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13643-021-01764-9","article-title":"Retention in opioid agonist treatment: A rapid review and meta-analysis comparing observational studies and randomized controlled trials","volume":"10","author":"Klimas","year":"2021","journal-title":"Syst. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.drugalcdep.2017.09.024","article-title":"Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment","volume":"181","author":"Haber","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000456612","article-title":"Randomised comparison of a novel oral lyophilisate versus existing buprenorphine sublingual tablets in opioid-dependent patients: A first-in-patient phase VII randomised open-label safety study","volume":"23","author":"Strang","year":"2017","journal-title":"Eur. Addict. Res."},{"key":"ref_71","first-page":"81","article-title":"Norbuprenorphine and respiratory depression: Exploratory analyses with new lyophilised buprenorphine and sublingual buprenorphine","volume":"56","author":"Strang","year":"2018","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_72","first-page":"19","article-title":"Switching between lyophilised and sublingual buprenorphine formulations in opioid-dependent patients: Observations on medication transfer during a safety and pharmacokinetic study","volume":"20","author":"Reed","year":"2018","journal-title":"Heroin Addict. Relat. Clin. Probl."},{"key":"ref_73","unstructured":"Medicines and Healthcare Products Regulatory Agency (MHRA) (2015). Public Assessment Report: Espranor 2 mg and 8 mg Oral Lyophilisate (Buprenorphine Hydrochloride), UK\/H\/5385\/001\u201302\/DC."},{"key":"ref_74","first-page":"31","article-title":"Impact of introducing an alternative buprenorphine formulation on opioid substitution therapy supervision within UK prison settings","volume":"260","author":"Langridge","year":"2022","journal-title":"Prison Serv. J."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Malta, M., Varatharajan, T., Russell, C., Pang, M., Bonato, S., and Fischer, B. (2019). Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review. PLoS Med., 16.","DOI":"10.1371\/journal.pmed.1003002"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jsat.2018.12.003","article-title":"Effectiveness of medication-assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review","volume":"99","author":"Moore","year":"2019","journal-title":"J. Subst. Abus. Treat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s11757-025-00895-2","article-title":"Efficacy of opioid maintenance in prison settings\u2014How strong is the evidence? A narrative review","volume":"19","author":"Soyka","year":"2025","journal-title":"Forens. Psychiatr. Psychol. Kriminol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40267-017-0408-8","article-title":"Buprenorphine oral lyophilisate (Espranor) in the substitution treatment of opioid dependence: A profile of its use","volume":"33","year":"2017","journal-title":"Drugs Ther. Perspect."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Perry, D., Kirkwood, J.E.M., Doroshuk, M.L., Kelmer, M., Korownyk, C.S., Ton, J., and Garrison, S.R. (2025). Opioid agonist therapy for opioid use disorder in primary versus specialty care. Cochrane Database Syst. Rev., 9.","DOI":"10.1002\/14651858.CD013672.pub2"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Nielsen, S., Tse, W.C., and Larance, B. (2022). Opioid agonist treatment for people who are dependent on pharmaceutical opioids. Cochrane Database Syst. Rev., 2022.","DOI":"10.1002\/14651858.CD011117.pub3"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/2\/270\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:44:02Z","timestamp":1770288242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/2\/270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":80,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ph19020270"],"URL":"https:\/\/doi.org\/10.3390\/ph19020270","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]}}}